Reviva Pharmaceuticals Holdings, Inc. (RVPH)
NASDAQ: RVPH · Real-Time Price · USD
1.380
+0.100 (7.81%)
At close: Sep 18, 2024, 4:00 PM
1.400
+0.020 (1.45%)
After-hours: Sep 18, 2024, 4:14 PM EDT

RVPH Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018
Selling, General & Admin
8.198.085.365.252.140.18
Upgrade
Research & Development
29.0531.4222.874.850.30.2
Upgrade
Operating Expenses
37.2439.528.2310.12.430.38
Upgrade
Operating Income
-37.24-39.5-28.23-10.1-2.43-0.38
Upgrade
Interest Expense
----0-1.45-0.47
Upgrade
Interest & Investment Income
0.520.50.18-0.080
Upgrade
Other Non Operating Income (Expenses)
0.74-0.24-0.191.590.03-
Upgrade
Pretax Income
-35.97-39.24-28.24-8.52-3.78-0.85
Upgrade
Income Tax Expense
0.020.020.020.0100
Upgrade
Net Income
-35.99-39.26-28.26-8.52-3.78-0.85
Upgrade
Net Income to Common
-35.99-39.26-28.26-8.52-3.78-0.85
Upgrade
Shares Outstanding (Basic)
2824201533
Upgrade
Shares Outstanding (Diluted)
2824201533
Upgrade
Shares Change (YoY)
30.40%21.94%31.95%383.10%10.60%-
Upgrade
EPS (Basic)
-1.29-1.65-1.45-0.58-1.24-0.31
Upgrade
EPS (Diluted)
-1.29-1.65-1.45-0.58-1.24-0.31
Upgrade
Free Cash Flow
-35.26-28.32-18.96-10.67-4.07-0.22
Upgrade
Free Cash Flow Per Share
-1.27-1.19-0.97-0.72-1.33-0.08
Upgrade
EBITDA
----10.1-2.43-0.38
Upgrade
D&A For EBITDA
---000
Upgrade
EBIT
-37.24-39.5-28.23-10.1-2.43-0.38
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.